Lilly The Latest To Latch On To Immunocore’s Bispecific Immunotherapy Approach
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Immunocore founder Bent Jakobsen explains why he thinks industry is coming around to the potential for targeting cancer with engineered bifunctional immunotherapies incorporating T-cell receptors.